Biomedical subjects

E Petrina

Publications and source records attributed to E Petrina.

4 recordsLinked to original sources

PubMed2004

[Acute nutritional problems in the oncology patient].

Alterations to the nutritional state are frequent in oncology patients. These constitute an important medical problem, with a tendency to rise in recent years. Some tumours usually appear more frequently in persons with prior malnutrition or excessive consumption of alcohol or tobacco. But besides, either because of the disease, or because of the treatment to which they are subjected, it is frequently the case that oncology patients show problems of deglutition and require the placement of probes for enteral nutrition. The present paper offers an initial evaluation of the nutritional state of these patients and, subsequently, of the most important problems that patients with enteral nutrition can present in emergencies.

Enteral Nutrition↗

PubMed2002

[Body composition and obesity].

Obesity is a disease that is characterised by a pathological excess of adipose tissue. Normally, this excess is measured according to its repercussion on weight and on the index of body mass. The methods for measuring body composition, some of which are of recent introduction, are showing the consequences on health of excess fat, especially visceral fat. A review is offered of the epidemiological markers of obesity, the techniques for evaluating fatty mass, the influence of the distribution of the adipose tissue and the factors that condition visceral fat, as well as the influence of this tissue on the metabolic profile of the obese patient.

English Abstract↗

PubMed2002

[Complications of obesity].

Obesity, which was evaluated positively in our culture in past periods and which was even considered by some to be merely an aesthetic question, is a disease with serious consequences for the health of the person suffering from it, and for the economy of those who have to meet its costs. Its present prevalence in Spain is situated around 13% and, if we can trust the forecasts established for other western countries such as the USA, it will increase to become the epidemic of the present century. The consequences of excess weight on the cardiovascular, respiratory, digestive, osteoarticular, reproductive and endocrine-metabolic systems are well known, as well as the relation between obesity and some types of cancer. As a general rule, it is worth bearing in mind that the greatest complications will correspond to the greater overweight (morbid obesity and severe obesity) and that age, the duration of ponderal excess and the distribution of the additional fat also have an influence, given that android/visceral/abdominal obesity is accompanied by the so-called insulin resistance syndrome. It is thus usually accompanied by hypertension, dyslipemia, alterations of hydrocarbonate tolerance and coagulation, elements involved as a whole in cardio-vascular morbi-mortality.

English Abstract↗

PubMedDate not supplied

[Administering toxins with antithyroids. Does this prevent recidivism of Graves disease? ].

There are three possibilities in the treatment of Graves-Basedow disease: antithyroids drugs, sub-total thyroidectomy and I131. In the USA there is a clear preference for definitive therapy with I131 once the thyrotoxicosis has been controlled. In Europe and Japan, however, the preference is for trying a conservative treatment, in the hope of inducing a permanent remission without recourse to radical methods. The most usual conservative pattern involves starting with high doses of antithyroids which are progressively reduced over the course of one year. The high rate of recurrence obtained with this method has fired the imagination of the endocrinologists in the search for other patterns that would provide more satisfactory results. One of these alternative patterns consists of combining thyroxine with antithyroids drugs. In this paper the characteristics of this combined pattern are reviewed. Following the justification, the clinical and experimental foundations on which it is based are outlined. Thirdly, details are given of clinical experiences taken from the medical literature and, finally, our own clinical experience is described after a five years follow up. It is concluded that: 1. The combined treatment delays the appearance of recurrence but does not reduce its frequency. 2. The addition of thyroxine alone following a course of combined treatment is not justified and 3. Prospective studies are needed in which hyperthyroid patients are grouped according to the variables that can affect recurrence.

English Abstract↗